Condition (MeSH)
Cachexia
ClinicalTrials.gov lists 300 trials for Cachexia or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
300 of the 300 trials are tagged with Cachexia itself; the rest are tagged with a narrower condition beneath it.
When did Cachexia trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 27
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 21 |
| 2025 | 15 |
| 2024 | 19 |
| 2023 | 14 |
| 2022 | 27 |
| 2021 | 19 |
| 2020 | 11 |
| 2019 | 10 |
| 2018 | 11 |
| 2017 | 11 |
Showing 10 of 28 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 24 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 34 months from start to primary completion across 29 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 177 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cachexia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 29 |
| Phase 1/2 | 2 |
| Phase 2 | 39 |
| Phase 2/3 | 8 |
| Phase 3 | 25 |
| Phase 4 | 3 |
| Not applicable | 107 |
| Observational | 87 |
How many Cachexia trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 11 |
| Recruiting | 45 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 9 |
| Completed | 159 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cachexia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 6 |
| GlaxoSmithKline | 5 |
| Helsinn Therapeutics (U.S.), Inc | 4 |
| Novartis Pharmaceuticals | 4 |
Which drugs are being tested for Cachexia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Anamorelin HCl | 8 |
| Ponsegromab | 5 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Megstrol Acetate | 12 |
| Standard Care | 4 |
| IM olanzapine | 4 |
| GSK2881078 | 3 |
| Exercise | 3 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cachexia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neoplasm progression | 107 | 4 |
| Non-small cell lung cancer | 68 | 2 |
| Pneumonia | 51 | 13 |
| Anaemia | 37 | 11 |
| Malignant neoplasm progression | 36 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Cachexia? (401)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Current findings and challenges on frailty, sarcopenia, and cachexia in older patients with heart failure: insights from the FRAGILE-HF study. | Journal of cardiology | 2026 | Yes |
| Quality of Life of Colorectal Cancer Patients Treated with Chemotherapy. | Nutrients | 2026 | Yes |
| Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2. | Journal of cachexia, sarcopenia and muscle | 2025 | Yes |
| Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | Yes |
| Patient-recorded indexing measurements (PRIMS) - study protocol of a prospective observational cohort study to improve the accuracy of the diagnosis of cancer cachexia. | BMC cancer | 2025 | Yes |
Showing 5 of 401 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.